COMBAT-ALS Trial Still Enrolling in North America

COMBAT-ALS Trial Still Enrolling in North America

303573

COMBAT-ALS Trial Still Enrolling in North America

MediciNova is still recruiting adults with early-stage amyotrophic lateral sclerosis (ALS) for the COMBAT-ALS Phase 2b/3 clinical trial evaluating its investigational oral therapy MN-166 (ibudilast). Patients are being enrolled at 19 sites across North America; more information about contacts and locations is available here. “We continue to enroll patients in our ongoing Phase 3 trial in ALS,” Yuichi Iwaki, MD, PhD, MediciNova’s president and CEO, said in a press release regarding the company’s 2021 second-quarter financial and business…

You must be logged in to read/download the full post.